Haemonetics
298 hedge funds and large institutions have $5.74B invested in Haemonetics in 2019 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 101 increasing their positions, 104 reducing their positions, and 24 closing their positions.
785% more call options, than puts
Call options by funds: $2.04M | Put options by funds: $230K
121% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 24
8% more funds holding
Funds holding: 275 → 298 (+23)
0.59% more ownership
Funds ownership: 98.05% → 98.64% (+0.59%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 104
9% less capital invested
Capital invested by funds: $6.28B → $5.74B (-$535M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
+$42.4M |
| 2 |
Morgan Stanley
New York
|
+$40.5M |
| 3 |
HM
HealthCor Management
New York
|
+$39.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.8M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$21.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
-$117M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$69.4M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$25.4M |
| 4 |
Renaissance Technologies
New York
|
-$22.6M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$17.8M |
HAE Hedge Fund Activity: Q4 2019 in Review
298 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q4 2019, worth a combined $5.74B — down 8.5% from $6.28B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new HAE positions and 24 closed out — a net gain of 29 holders — while 101 added to existing stakes and 104 trimmed.
The largest buyer was Neuberger Berman Group, adding an estimated $42.4M. The largest seller was American Century Companies, exiting entirely with an estimated $117M sold.
- 298 institutional investors held Haemonetics (HAE) as of Q4 2019, up from 275 in Q3 2019.
- Funds reported $5.74B of Haemonetics stock for Q4 2019, down 8.5% quarter-over-quarter.
- 53 funds opened new Haemonetics positions in Q4 2019 and 24 closed out, a net change of +29 holders.
- The largest Haemonetics buyer in Q4 2019 was Neuberger Berman Group, an estimated $42.4M added.
- The largest Haemonetics seller in Q4 2019 was American Century Companies, an estimated $117M sold.
Based on aggregated 13F filings for Q4 2019.